305 related articles for article (PubMed ID: 36766760)
1. Survival Mechanisms of Metastatic Melanoma Cells: The Link between Glucocorticoids and the Nrf2-Dependent Antioxidant Defense System.
Obrador E; Salvador-Palmer R; López-Blanch R; Oriol-Caballo M; Moreno-Murciano P; Estrela JM
Cells; 2023 Jan; 12(3):. PubMed ID: 36766760
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid receptor antagonism overcomes resistance to BRAF inhibition in BRAF
Estrela JM; Salvador R; Marchio P; Valles SL; López-Blanch R; Rivera P; Benlloch M; Alcácer J; Pérez CL; Pellicer JA; Obrador E
Am J Cancer Res; 2019; 9(12):2580-2598. PubMed ID: 31911848
[TBL] [Abstract][Full Text] [Related]
3.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
4. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo.
Niessner H; Burkard M; Leischner C; Renner O; Plöger S; Meraz-Torres F; Böcker M; Hirn C; Lauer UM; Venturelli S; Busch C; Sinnberg T
Cells; 2022 Apr; 11(7):. PubMed ID: 35406796
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
7. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
8. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
10. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
[TBL] [Abstract][Full Text] [Related]
11. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
12. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid receptor knockdown decreases the antioxidant protection of B16 melanoma cells: an endocrine system-related mechanism that compromises metastatic cell resistance to vascular endothelium-induced tumor cytotoxicity.
Obrador E; Valles SL; Benlloch M; Sirerol JA; Pellicer JA; Alcácer J; Coronado JA; Estrela JM
PLoS One; 2014; 9(5):e96466. PubMed ID: 24802641
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
